2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 296

Different Patterns of Involvement of Thigh Muscles in Dermatomyositis and Polymyositis Using Fat-Suppressed Magnetic Resonance Sequences
Abstract Number: 2202

Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE – Associations with Different Clinical Outcomes
Abstract Number: 3258

Different Perception of Disease Activity in Multimorbid Rheumatoid Arthritis Patients
Abstract Number: 2317

Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations
Abstract Number: 2646

Different Wording of the Patient Global Assessment Scale Leads to Different Rating of Disease Activity
Abstract Number: 1260

Differential DNA Methylation and Reduced Expression of Transcription Factors in Human OA Cartilage
Abstract Number: 1245

Differential DNA Methylation Associated with Lupus Nephritis Shows Enrichment in Genes Involved in Regulation of TH2 Differentiation and Renal Development
Abstract Number: 3099

Differential Effects of IL-6 Blockade Tocilizumab and TNF Inhibitors on the Reduced Angiogenesis and Lining Layer Degeneration in Synovial Tissues from Patients with Rheumatoid Arthritis
Abstract Number: 1391

Differential Expression of Interferon Gamma in Exudate from Hidradenitis Suppurativa Lesions Compared to Chronic Wounds
Abstract Number: 1249

Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells
Abstract Number: 1139

Differential Inflammatory Profile in Experimental Models of Arthritis
Abstract Number: 1920

Differential Production of Th17-Related Cytokines By Toll like Receptor (TLR)-Ligands-Stimulated Monocyte-Derived Dendritic Cells (Mo-DCs) from Systemic Sclerosis (SSc) Patients; Relevance of IL-22 and IL-33 According to Disease Subtype and Stage
Abstract Number: 2949

Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study
Abstract Number: 1010

Differing Perspectives Between Doctor, Nurse and Patient Views on Professionalism and Empathy: An Inter-Professional 360-Degree Rheumatology Objective Structured Clinical Examination
Abstract Number: 2945

Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].